Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mentoring | 1 | 2023 | 81 | 0.730 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 204 | 0.590 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 2025 | 9 | 0.460 |
Why?
|
| Internship and Residency | 2 | 2023 | 1248 | 0.410 |
Why?
|
| Smoldering Multiple Myeloma | 2 | 2024 | 4 | 0.410 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 414 | 0.350 |
Why?
|
| Emergency Medical Services | 3 | 2022 | 418 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 261 | 0.330 |
Why?
|
| Papillomavirus Infections | 2 | 2024 | 385 | 0.260 |
Why?
|
| Bayes Theorem | 2 | 2024 | 311 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 2 | 2018 | 264 | 0.230 |
Why?
|
| Hydrogen Sulfide | 1 | 2024 | 13 | 0.220 |
Why?
|
| Varenicline | 1 | 2024 | 12 | 0.220 |
Why?
|
| Golgi Apparatus | 1 | 2024 | 95 | 0.220 |
Why?
|
| Models, Statistical | 2 | 2024 | 492 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1342 | 0.210 |
Why?
|
| Camping | 1 | 2004 | 14 | 0.210 |
Why?
|
| Mass Screening | 4 | 2024 | 830 | 0.210 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 1539 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2024 | 190 | 0.200 |
Why?
|
| Age of Onset | 1 | 2024 | 621 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 106 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 102 | 0.190 |
Why?
|
| Oligopeptides | 2 | 2021 | 116 | 0.190 |
Why?
|
| Advance Care Planning | 1 | 2022 | 41 | 0.190 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2648 | 0.180 |
Why?
|
| Communication | 2 | 2023 | 544 | 0.180 |
Why?
|
| Maternal-Fetal Relations | 1 | 2021 | 17 | 0.180 |
Why?
|
| Parturition | 1 | 2021 | 66 | 0.170 |
Why?
|
| Aged | 16 | 2024 | 21406 | 0.170 |
Why?
|
| Dexamethasone | 2 | 2021 | 276 | 0.170 |
Why?
|
| Indazoles | 1 | 2020 | 31 | 0.170 |
Why?
|
| Computer Simulation | 1 | 2024 | 697 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2026 | 629 | 0.170 |
Why?
|
| Deoxycytidine | 1 | 2020 | 83 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 1828 | 0.160 |
Why?
|
| Curriculum | 2 | 2023 | 772 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 688 | 0.160 |
Why?
|
| Vagina | 1 | 2021 | 205 | 0.160 |
Why?
|
| Humans | 32 | 2026 | 132061 | 0.160 |
Why?
|
| Football | 1 | 2019 | 36 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 242 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 129 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 489 | 0.150 |
Why?
|
| Middle Aged | 16 | 2024 | 28964 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2020 | 285 | 0.150 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 140 | 0.140 |
Why?
|
| Heart Conduction System | 1 | 2019 | 167 | 0.140 |
Why?
|
| Teaching Rounds | 1 | 2018 | 33 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 632 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 271 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2020 | 418 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2026 | 1199 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 157 | 0.130 |
Why?
|
| Female | 21 | 2026 | 70712 | 0.130 |
Why?
|
| Adult | 15 | 2026 | 31568 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 553 | 0.130 |
Why?
|
| Microbiota | 1 | 2021 | 434 | 0.120 |
Why?
|
| Genomics | 1 | 2024 | 1646 | 0.120 |
Why?
|
| Parents | 1 | 2023 | 1078 | 0.120 |
Why?
|
| Biomarkers | 1 | 2026 | 3406 | 0.120 |
Why?
|
| Lymphoma, Follicular | 1 | 2016 | 30 | 0.120 |
Why?
|
| Simulation Training | 1 | 2018 | 152 | 0.120 |
Why?
|
| Male | 19 | 2026 | 64922 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1738 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 80 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1658 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2849 | 0.120 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2018 | 268 | 0.110 |
Why?
|
| Trauma, Nervous System | 1 | 2014 | 5 | 0.110 |
Why?
|
| Vertebral Artery Dissection | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3350 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2016 | 327 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 144 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 153 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 189 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 811 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 301 | 0.100 |
Why?
|
| Smoking | 1 | 2018 | 938 | 0.100 |
Why?
|
| Young Adult | 6 | 2026 | 9957 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 7102 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 6229 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2019 | 1580 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 758 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 918 | 0.090 |
Why?
|
| Disease Management | 1 | 2014 | 561 | 0.080 |
Why?
|
| Child | 4 | 2026 | 25789 | 0.080 |
Why?
|
| Adolescent | 7 | 2026 | 20562 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1213 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2024 | 1009 | 0.070 |
Why?
|
| Transcriptome | 2 | 2025 | 1125 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3761 | 0.060 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2026 | 23 | 0.060 |
Why?
|
| United Kingdom | 2 | 2018 | 235 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2026 | 6567 | 0.060 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2024 | 14 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1183 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 3681 | 0.050 |
Why?
|
| Binomial Distribution | 1 | 2023 | 5 | 0.050 |
Why?
|
| Michigan | 1 | 2004 | 50 | 0.050 |
Why?
|
| Utilization Review | 1 | 2004 | 40 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2026 | 652 | 0.050 |
Why?
|
| Kentucky | 1 | 2023 | 28 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5409 | 0.050 |
Why?
|
| Cause of Death | 2 | 2016 | 510 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 3990 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 327 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 260 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 354 | 0.050 |
Why?
|
| Spouse Abuse | 1 | 2002 | 16 | 0.050 |
Why?
|
| Risk Factors | 3 | 2026 | 10941 | 0.050 |
Why?
|
| Motor Vehicles | 1 | 2002 | 11 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2022 | 97 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2002 | 111 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2026 | 1234 | 0.040 |
Why?
|
| Patient Admission | 1 | 2002 | 184 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2146 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 2002 | 140 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1491 | 0.040 |
Why?
|
| United States | 3 | 2024 | 11658 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 329 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 358 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 745 | 0.040 |
Why?
|
| Age Factors | 1 | 2026 | 2912 | 0.040 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2022 | 669 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 393 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 1018 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 424 | 0.040 |
Why?
|
| Genotype | 1 | 2024 | 2697 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2021 | 1035 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 136 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 307 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 96 | 0.030 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 89 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2018 | 183 | 0.030 |
Why?
|
| Focus Groups | 1 | 2018 | 224 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 1882 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 749 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 292 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 437 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 356 | 0.030 |
Why?
|
| Social Class | 1 | 2018 | 204 | 0.030 |
Why?
|
| Death Certificates | 1 | 2016 | 10 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1450 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1728 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 390 | 0.030 |
Why?
|
| Prevalence | 2 | 2019 | 2658 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 18507 | 0.030 |
Why?
|
| Infant | 2 | 2026 | 13064 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2004 | 1170 | 0.030 |
Why?
|
| Incidence | 1 | 2023 | 3380 | 0.030 |
Why?
|
| South Carolina | 1 | 2015 | 10 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 134 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2026 | 14751 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 18 | 0.030 |
Why?
|
| Mastectomy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Phenotype | 1 | 2024 | 4529 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 242 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 808 | 0.030 |
Why?
|
| Prostate | 1 | 2016 | 434 | 0.030 |
Why?
|
| Time Factors | 1 | 2004 | 6448 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 945 | 0.030 |
Why?
|
| Brain | 1 | 2025 | 3183 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1032 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 719 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2674 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 698 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2016 | 17419 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 4757 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1297 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 576 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 34882 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 898 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2018 | 791 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2014 | 377 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2018 | 13028 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2057 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 741 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5164 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7566 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2014 | 800 | 0.020 |
Why?
|
| Traumatology | 1 | 2002 | 25 | 0.010 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 90 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2002 | 230 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 828 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 147 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2002 | 199 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 588 | 0.010 |
Why?
|
| Physician's Role | 1 | 2002 | 169 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 249 | 0.010 |
Why?
|
| General Surgery | 1 | 2002 | 226 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 415 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2002 | 716 | 0.010 |
Why?
|
| Length of Stay | 1 | 2002 | 1379 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 3091 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2172 | 0.010 |
Why?
|